Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Veruska L Fook-Alves

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Biochimica Et Biophysica Acta|April 2, 2016
TP53 Regulated Inhibitor of Apoptosis 1 (TRIAP1) stable silencing increases late apoptosis by upregulation of caspase 9 and APAF1 in RPMI8226 multiple myeloma cell lineVeruska L Fook-Alves, Mariana Bleker de Oliveira, Daniela B Zanatta, et al.
Biochemical and Biophysical Research Communications|September 22, 2019
Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell linesRebecca S S Barbosa, Paola M Dantonio, Taís Guimarães, et al.
Cancer Letters|June 25, 2017
Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patientsMariana B de Oliveira, Veruska L Fook-Alves, Angela I P Eugenio, et al.
Oncotarget|December 20, 2015
Angiomirs expression profiling in diffuse large B-Cell lymphomaNatália M Borges, Marcela do Vale Elias, Veruska L Fook-Alves, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Biochimica Et Biophysica Acta|April 2, 2016
TP53 Regulated Inhibitor of Apoptosis 1 (TRIAP1) stable silencing increases late apoptosis by upregulation of caspase 9 and APAF1 in RPMI8226 multiple myeloma cell lineVeruska L Fook-Alves, Mariana Bleker de Oliveira, Daniela B Zanatta, et al.
Biochemical and Biophysical Research Communications|September 22, 2019
Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell linesRebecca S S Barbosa, Paola M Dantonio, Taís Guimarães, et al.
Cancer Letters|June 25, 2017
Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patientsMariana B de Oliveira, Veruska L Fook-Alves, Angela I P Eugenio, et al.
Oncotarget|December 20, 2015
Angiomirs expression profiling in diffuse large B-Cell lymphomaNatália M Borges, Marcela do Vale Elias, Veruska L Fook-Alves, et al.
Pageof 1